CANADY HELIOS COLD PLASMA™ TECHNOLOGY
FOR THE TREATMENT OF CANCER*
IN 2024 IN THE U.S.,
The American Cancer Society estimates 2,001,120 new cancer cases and 611,760 cancer deaths.
Estimated new cancers (2024) – ACS
TUMOR REMOVAL
Often treatment protocol dictates surgical removal of the cancerous tumor along with a “margin” of healthy tissue to ensure all of the cancer has been removed.
CANCEROUS MARGINS
When a surgeon excises cancerous tissue there is never a “guarantee” that there isn’t microscopic cancer cells left behind at the surgical margins.
*For FDA Investigational Use Only
THE SOLUTION:
CANADY COLD PLASMA™ TECHNOLOGY
CANADY HELIOS™ COLD PLASMA SCALPEL and CP-1000 GENERATOR
USMI sees tremendous potential for the application of Canady Cold Atmospheric Plasma in the treatment of the surgical site immediately following the removal of a cancerous tumor.
USMI is the first company in the world to integrate a high-frequency electrosurgical generator and plasma gas to deliver Cold Atmospheric Plasma (CAP) for the selective treatment of Cancer.
(US Patent No. 10,023,858 B2, July 2019)
The Canady Cold Plasma™ spray is a non-thermal process that triggers chemical-molecular changes in cancer cells, leading to apoptosis (cell death), while healthy human tissue and cells are left unharmed.
THE CANADY COLD PLASMA™ PROCEDURE
Cancerous Tumor Located in Breast
Tumor Removed with Canady Hybrid Plasma™ Scalpel
Tumor Cavity and Margins Sprayed with Canady Helios™ Cold Plasma for 2-6 minutes depending on cancer type.
Microscopic Cancer Cells are targeted with the Canady Helios™ Cold Plasma
*For FDA Investigational Use Only
COLD PLASMA VIDEOS
USMI’s Cold Plasma Technology Featured on Fox News
USMI’s Cold Plasma Trailer
Amelda’s Story: Inoperable Liver Cancer